姜长涛 - 北京大学 - 基础医学院

个人简介

姜长涛教授长期从事代谢性疾病的发病机制与转化医学研究，重点关注肠道微生态在其中的作用。以通讯作者在Nature（2022）、Nature Medicine（2019, 2018, 2017）、Cell Metabolism（2021a, 2021b, 2019）、Journal of Clinical Investigation（2021）等杂志发表SCI论文二十余篇，获授权发明专利6项，受邀在Nature Review Endocrinology、Gastroenterology、Protein & Cell及Small Methods等期刊撰写综述4篇。入选国家杰出青年科学基金获得者、教育部青年长江学者、国家“万人计划”青年拔尖人才等人才计划，获得第十六届中国青年科技奖、第八届树兰医学青年奖、第六届北美华人糖尿病学会（CADA）青年科学家奖、第二十三届茅以升北京青年科技奖等奖励，主持国家自然科学基金重点项目、重大研究计划及国家重点研发计划等十余项基金，作为PI获得国家自然科学基金创新研究群体项目；作为大会主席，主办中国科协第295次青年科学家论坛“代谢调控与靶标发现前沿会”、2021年中国肠道大会、首届中国肥胖大会基础专场等大型国际、国内会议，并担任中国生物物理学会肠道菌群分会秘书长、北京生理学会生理专业委员会主任委员、《遗传》杂志副主编、《Science Bulletin》杂志编委等学术职务。

研究领域

肠道微生物与代谢性疾病的发病机制研究

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1) Chen B#, Sun L#, Zeng G#, Shen Z#, Wang K#, Yin L#, Xu F, Wang P, Ding Y, Nie Q, Wu Q, Zhang Z, Xia J, Lin J, Luo Y, Cai J, Krausz K, Zheng R, Xue Y, Zheng MH*, Li Y*, Yu C*, Gonzalez FJ*, Jiang CT*. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature. 2022 Oct;610(7932):562-568. 2) Sun L#, Xie C#, Wang G#, Wu Y#, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X, Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J, Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang CT*. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018 Dec;24(12):1919-1929. (Highly cited paper, data from Essential Science Indicators; Commentaries and editorials from Nat Med. 2018, Cell Metab. 2018, Nat Rev Endocrinol. 2018) 3) Zhang X#, Zhang Y#, Wang P#, Zhang SY#, Dong Y, Zeng G, Yan Y, Sun L, Wu Q, Liu H, Liu B, Kong W, Wang X, Jiang CT*. Adipocyte hypoxia-inducible factor 2α suppresses atherosclerosis by promoting adipose ceramide catabolism. Cell Metab. 2019 Nov 5;30(5):937-951. 4) Wu Q#, Liang X#, Wang K#, Lin J, Wang X, Wang P, Zhang Y, Nie Q, Liu H, Zhang Z, Liu J, Pang Y, Jiang CT*. Intestinal hypoxia-inducible factor 2α regulates lactate levels to shape the gut microbiome and alter thermogenesis. Cell Metab. 2021 Oct 5;33(10):1988-2003. 5) Wu Q#, Sun L#, Hu X, Wang X, Xu F, Chen B, Liang X, Xia J, Wang P, Aibara D, Zhao S, Zeng G, Yun C, Yan Y, Zhu Y, Bustin M, Zhang SY*, Gonzalez FJ*, Jiang CT*. Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis. J Clin Invest. 2021 May 3;131(9):e142865. 6) Qi X#, Yun C#, Sun L, Xia J, Wu Q, Wang Y, Wang L, Zhang Y, Liang X, Wang L, Gonzalez FJ, Patterson AD, Liu H, Mu L, Zhou Z, Zhao Y, Li R, Liu P, Zhong C, Pang Y*, Jiang CT*, Qiao J*. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019 Aug;25(8):1225-1233. (Commentaries and editorials from Nat Med. 2019, Cell Metab. 2019, Nat Rev Drug Discov. 2019) 7) Zheng X#, Chen T#, Jiang R#, Zhao A#, Wu Q, Kuang J, Sun D, Ren Z, Li M, Zhao M, Wang S, Bao Y, Li H, Hu C, Dong B, Li D, Wu J, Xia J, Wang X, Lan K, Rajani C, Xie G, Lu A, Jia WP*, Jiang CT*, Jia W*. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 2021 Apr 6;33(4):791-803. (Highly cited paper, data from Essential Science Indicators) 8) Xie C, Yagai T, Luo Y, Liang X, Chen T, Wang Q, Sun D, Zhao J, Ramakrishnan SK, Sun L, Jiang C, Xue X, Tian Y, Krausz KW, Patterson AD, Shah YM, Wu Y*, Jiang CT*, Gonzalez FJ*. Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23(11):1298-1308. (Commentaries and editorials from Nat Med. 2017, Nat Rev Gastroenterol Hepatol. 2017) 9) Liu H, Xu F, Gao Y, Pang Y, Xie C*, Jiang CT*. An integrated LC-MS/MS strategy for quantifying the oxidative-redox metabolome in multiple biological samples. Anal Chem. 2020 Jul 7;92(13):8810-8818. 10) Zhang SY, Lv Y, Zhang H, Gao S, Wang T, Feng J, Wang Y, Liu G, Xu MJ, Wang X*, Jiang CT*. Adrenomedullin 2 improves early obesity-induced adipose insulin resistance by inhibiting the class II MHC in adipocytes. Diabetes. 2016 Aug;65(8):2342-2355.